≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Supernumerary ureter

Endpoint Browser PheWeb

Q17_SUPERNUMERARY_URETER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q62.5
  • Cause of death: ICD-10 — Q62.5

2 out of 7 registries used, show all original rules.

68

4. Check minimum number of events

None

68

5. Include endpoints

None

68

6. Filter based on genotype QC (FinnGen only)

66

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Similar endpoints

↥

List of similar endpoints to Supernumerary ureter based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Similar with more cases:

Venn diagram with a set fully inside an highlighted set Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 66 57 9
Unadjusted period prevalence (%) 0.02 0.02 0.00
Median age at first event (years) 18.30 14.38 43.13

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
68
Matched controls
680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q62.5
ICD-10 Finland
Duplication of ureter
+∞
97.7
68
*
UKC02
NOMESCO Finland
Cystoscopy
16.4
29.4
33
37
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
7.4
12.6
23
44
J01EA01
ATC
trimethoprim; systemic
5.9
12.3
37
114
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
15.8
11.2
18
15
Q62.7
ICD-10 Finland
Congenital vesico-uretero-renal reflux
129.1
10.7
11
*
1530
FHL
Urethrocystoscopy
57.7
8.9
10
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
4.8
8.2
24
69
KBH20
NOMESCO Finland
Replantation of ureter
76.8
6.5
7
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Urology
34 [38004474]
—
—
—
1.0e+50
—
3.4e+00
2.0e+00
—
—
—
—
—
—
cases:30.77%
controls:0.00%
—
—
cases:23.08%
controls:0.99%
cases:17.31%
controls:2.62%
—
—
—
16
0
36
506
—
12
5
40
501
9
13
43
484
General Surgery
2 [38004447]
7.7e-01
1.6e+00
—
1.0e+50
2.2e+00
1.7e+00
1.0e+00
cases:23.53%
controls:12.45%
cases:21.15%
controls:5.14%
—
—
cases:15.38%
controls:0.00%
cases:9.62%
controls:1.19%
cases:21.15%
controls:4.74%
cases:30.77%
controls:14.08%
12
62
39
436
11
26
41
480
—
8
0
44
506
5
6
47
500
11
24
41
482
16
70
36
427
Outpatient Visit
OP [9202]
3.8e-01
4.8e-01
9.0e-02
—
1.4e+00
1.2e+00
8.4e-01
cases:68.63%
controls:59.84%
cases:57.69%
controls:45.65%
cases:13.46%
controls:12.45%
—
—
cases:32.69%
controls:10.28%
cases:73.08%
controls:45.06%
cases:84.62%
controls:70.42%
35
298
16
200
30
231
22
275
7
63
45
443
—
17
52
35
454
38
228
14
278
44
350
8
147
Case Management Agency
251B00000X [38004193]
2.3e-01
7.7e-02
5.8e-01
2.6e+00
3.6e-02
-1.8e-02
-6.0e-02
cases:43.14%
controls:37.55%
cases:32.69%
controls:31.03%
cases:21.15%
controls:13.04%
cases:15.38%
controls:1.38%
cases:13.46%
controls:13.04%
cases:36.54%
controls:36.96%
cases:50.00%
controls:51.51%
22
187
29
311
17
157
35
349
11
66
41
440
8
7
44
499
7
66
45
440
19
187
33
319
26
256
26
241
Other and unspecified abdominal pain
R10.4 [45568113]
2.2e+00
—
—
—
—
—
9.4e-01
cases:17.65%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:6.64%
9
11
42
487
—
—
—
—
—
8
33
44
464
Urinary tract infection, site not specified
N39.0 [45548665]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:2.41%
—
—
—
—
—
—
8
12
44
485
Pediatric Surgery
OMOP4822020 [45756819]
—
—
—
1.0e+50
—
—
1.6e+00
—
—
—
—
—
—
cases:9.62%
controls:0.00%
—
—
—
—
cases:17.31%
controls:4.02%
—
—
—
5
0
47
506
—
—
9
20
43
477
trimethoprim; oral, parenteral
J01EA01 [21602931]
1.6e+00
—
—
—
—
—
7.8e-01
cases:23.53%
controls:5.82%
—
—
—
—
—
—
—
—
—
—
cases:13.46%
controls:6.64%
12
29
39
469
—
—
—
—
—
7
33
45
464
Outpatient Hospital
22 [8756]
5.9e-01
6.5e-01
-1.0e+50
1.0e+50
—
1.1e+00
7.1e-01
cases:35.29%
controls:23.29%
cases:15.38%
controls:8.70%
cases:0.00%
controls:1.19%
cases:17.31%
controls:0.00%
—
—
cases:19.23%
controls:7.11%
cases:25.00%
controls:14.08%
18
116
33
382
8
44
44
462
0
6
52
500
9
0
43
506
—
10
36
42
470
13
70
39
427
hydrochlorothiazide; oral
C03AA03 [21601466]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
Headache
N01 [2002000720]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
6
51
492
—
—
—
—
0
6
52
500
—
Asthma
J45 [45596282]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.82%
0
5
51
493
—
—
—
—
—
0
14
52
483
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
2.2e-01
5.6e-01
—
—
—
5.0e-01
8.8e-02
cases:11.76%
controls:9.64%
cases:9.62%
controls:5.73%
—
—
—
—
—
—
cases:11.54%
controls:7.31%
cases:19.23%
controls:17.91%
6
48
45
450
5
29
47
477
—
—
—
6
37
46
469
10
89
42
408
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-2.0e-01
3.4e-01
—
—
—
4.4e-01
2.2e-01
cases:13.73%
controls:16.27%
cases:11.54%
controls:8.50%
—
—
—
—
—
—
cases:15.38%
controls:10.47%
cases:26.92%
controls:22.74%
7
81
44
417
6
43
46
463
—
—
—
8
53
44
453
14
113
38
384
Viral intestinal infection, unspecified
A08.4 [45576230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Laboratory test
15220000 [4034850]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.02%
—
0
5
52
501
—
—
—
—
0
15
52
482
Lipid panel - Serum or Plasma
100898-6 [1761868]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
—
0
11
52
495
—
—
—
—
—
insulin lispro; parenteral
A10AD04 [21600732]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
0
6
52
500
—
0
9
52
497
—
—
Cerebral infarction, unspecified
I63.9 [45596216]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
F79.0 [45566855]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.41%
—
—
—
—
—
0
5
52
501
0
7
52
490
Public health laboratory ask at order entry panel
81959-9 [21494755]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.41%
—
—
—
—
—
0
5
52
501
0
7
52
490
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
-1.2e-01
2.9e-01
—
—
—
3.8e-01
1.1e-01
cases:13.73%
controls:15.26%
cases:11.54%
controls:8.89%
—
—
—
—
—
—
cases:15.38%
controls:11.07%
cases:28.85%
controls:26.56%
7
76
44
422
6
45
46
461
—
—
—
8
56
44
450
15
132
37
365
Ear microscopy
UDC00 [2001301558]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
0
11
52
486
etoricoxib; oral
M01AH05 [21603996]
—
—
—
—
—
—
6.8e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:10.87%
—
—
—
—
—
—
6
54
46
443
chorionic gonadotrophin; parenteral
G03GA01 [21602599]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:5.84%
—
0
9
52
497
—
—
—
—
0
29
52
468
Scheduled procedure
ZXD10 [2001311387]
—
-1.0e+50
—
1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
cases:9.62%
controls:0.00%
—
—
—
—
—
—
—
0
7
52
499
—
5
0
47
506
—
—
—
nortriptyline; oral, parenteral
N06AA10 [21604697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
glucosamine; oral
M01AX05 [21604002]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
9
51
489
—
—
—
—
0
5
52
501
—
ibuprofen
R02AX02 [1588667]
-1.1e-01
2.0e-01
—
—
—
3.1e-01
2.1e-01
cases:21.57%
controls:23.49%
cases:13.46%
controls:11.26%
—
—
—
—
—
—
cases:13.46%
controls:10.28%
cases:32.69%
controls:28.17%
11
117
40
381
7
57
45
449
—
—
—
7
52
45
454
17
140
35
357
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
—
—
—
—
—
1.2e+00
3.4e-01
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:3.95%
cases:15.38%
controls:11.47%
—
—
—
—
—
6
20
46
486
8
57
44
440
Acute bronchitis
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
saccharomyces boulardii; oral
A07FA02 [21600670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
General anaesthesia
WX402 [2001310806]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:2.01%
—
—
—
—
—
—
5
10
47
487
pH of Capillary blood
2745-8 [3009343]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Restricted health certificate
SPAT1283 [2001700384]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
487
—
—
—
—
—
—
Cough
R05 [2002000886]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
0
10
51
488
—
—
—
—
—
0
10
52
487
insulin aspart; parenteral
A10AD05 [21600733]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:3.75%
cases:0.00%
controls:0.99%
—
—
—
—
cases:0.00%
controls:3.95%
cases:0.00%
controls:7.24%
—
0
19
52
487
0
5
52
501
—
—
0
20
52
486
0
36
52
461
Other specified intervertebral disc degeneration
M51.3 [45591865]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
Small restoration
SFA00 [2001310357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
489
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
5
52
501
—
—
—
—
—
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
52
500
—
Lymphoid leukaemia
C91 [45586062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
triamcinolone and antiseptics
D07BB03 [21602150]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
52
500
—
Pediatric Medicine
37 [38004477]
1.1e-01
9.1e-02
—
—
—
-2.1e-01
-1.3e-01
cases:19.61%
controls:17.87%
cases:15.38%
controls:14.23%
—
—
—
—
—
—
cases:11.54%
controls:13.83%
cases:15.38%
controls:17.10%
10
89
41
409
8
72
44
434
—
—
—
6
70
46
436
8
85
44
412
clonazepam; oral, parenteral
N03AE01 [21604415]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.41%
—
—
—
—
—
0
5
52
501
0
7
52
490
lercanidipine; oral
C08CA13 [21601759]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
-1.0e+50
—
—
—
—
—
8.2e-01
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:5.43%
0
8
51
490
—
—
—
—
—
6
27
46
470
hydrocortisone and antiseptics
D07BA04 [21602146]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
52
500
—
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
52
501
—
mometasone
D07AC13 [21602132]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:3.02%
—
—
—
—
—
—
5
15
47
482
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
desloratadine; oral
R06AX27 [21603526]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.43%
—
—
—
—
—
—
5
22
47
475
Chronic gingivitis
K05.1 [45605912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Plugged feeling ear
H13 [2002000480]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.62%
0
8
51
490
—
—
—
—
—
0
13
52
484
Periodontal treatment, very brief
SDA01 [2001310326]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
0
8
52
498
—
—
—
—
—
mometasone; nasal
R01AD09 [21605051]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:8.05%
—
—
—
—
—
—
5
40
47
457
Skin texture symptom/complaint
S21 [2002000986]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
5
51
493
—
—
—
—
—
0
6
52
491
pseudoephedrine, combinations; oral
R01BA52 [21603213]
5.2e-01
—
—
—
—
-1.0e+50
6.7e-01
cases:17.65%
controls:11.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.96%
cases:19.23%
controls:10.87%
9
56
42
442
—
—
—
—
0
15
52
491
10
54
42
443
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
rizatriptan; oral
N02CC04 [21604379]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:5.43%
—
—
—
—
—
—
5
27
47
470
Lump/swelling localized
S04 [2002000969]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
7
52
490
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.41%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
0
7
51
491
0
5
52
501
—
—
—
0
9
52
497
—
furosemide; oral, parenteral
C03CA01 [21601518]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
0
5
52
501
—
—
celecoxib; oral
M01AH01 [21603992]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Retained dental root
K08.3 [45543292]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Hallux valgus (acquired)
M20.1 [45606152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
chlorhexidine
S03AA04 [21605193]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
52
500
—
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Leiomyoma of uterus, unspecified
D25.9 [45542693]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
0
11
52
486
Acute vaginitis
N76.0 [45543891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Peritonsillar abscess
J36 [45581858]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Emergency Medicine
93 [38004510]
—
—
—
—
—
—
4.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:17.31%
controls:12.07%
—
—
—
—
—
—
9
60
43
437
Preventive oral health care, extensive
SCA03 [2001310304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
0
9
52
488
Naevus/mole
S82 [2002001046]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
Cystitis/urinary infection other
U71 [2002001191]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
5
51
493
—
—
—
—
—
0
6
52
491
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.2e-01
—
—
—
—
—
3.2e-01
cases:9.80%
controls:8.03%
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:11.67%
5
40
46
458
—
—
—
—
—
8
58
44
439
Fitting of hearing aid
DAX08 [2001301529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
5
52
501
—
—
—
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-1.2e-01
2.5e-01
1.7e+00
—
—
3.7e-01
1.3e-01
cases:17.65%
controls:19.48%
cases:17.31%
controls:14.03%
cases:11.54%
controls:2.37%
—
—
—
—
cases:21.15%
controls:15.61%
cases:32.69%
controls:29.98%
9
97
42
401
9
71
43
435
6
12
46
494
—
—
11
79
41
427
17
149
35
348
Dysphagia
R13 [45573013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Hypersensitivity skin testing
268377001 [4147813]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Periodic health check-up of children and adolescents
SPAT1315 [2001700416]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
—
0
7
52
499
—
—
—
—
—
cefalexin; oral
J01DB01 [21602870]
-1.1e-01
8.6e-01
—
—
—
1.0e+00
2.2e-01
cases:25.49%
controls:27.71%
cases:15.38%
controls:7.11%
—
—
—
—
—
—
cases:17.31%
controls:7.11%
cases:28.85%
controls:24.55%
13
138
38
360
8
36
44
470
—
—
—
9
36
43
470
15
122
37
375
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Polyarthrosis
M15 [45596490]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Personal history of leukaemia
Z85.6 [45609980]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.20%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.41%
0
6
51
492
0
5
52
501
—
—
—
0
5
52
501
0
7
52
490
Other healthcare associate professional
Z3229 [2001311561]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
489
—
—
—
—
—
—
Acute suppurative otitis media
H66.0 [45572040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
glucagon; nasal, parenteral
H04AA01 [21602778]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
—
—
—
—
—
0
10
52
496
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:6.24%
—
—
—
—
—
—
8
31
44
466
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
1.1e-02
—
—
—
—
6.6e-01
-1.1e-01
cases:11.76%
controls:11.65%
—
—
—
—
—
—
—
—
cases:11.54%
controls:6.32%
cases:15.38%
controls:16.90%
6
58
45
440
—
—
—
—
6
32
46
474
8
84
44
413
Conjunctival surface anesthesia
WX100 [2001310764]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
5.6e-01
8.0e-01
—
—
—
7.7e-01
7.8e-01
cases:9.80%
controls:5.82%
cases:11.54%
controls:5.53%
—
—
—
—
—
—
cases:13.46%
controls:6.72%
cases:15.38%
controls:7.65%
5
29
46
469
6
28
46
478
—
—
—
7
34
45
472
8
38
44
459
Tooth plaque
K03.66 [2000502691]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
0
5
51
493
—
—
—
—
—
0
10
52
487
Infectious Disease
44 [38004484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
-1.2e-01
5.6e-01
-1.0e+50
—
—
1.4e-01
2.9e-01
cases:11.76%
controls:13.05%
cases:9.62%
controls:5.73%
cases:0.00%
controls:1.19%
—
—
—
—
cases:9.62%
controls:8.50%
cases:23.08%
controls:18.31%
6
65
45
433
5
29
47
477
0
6
52
500
—
—
5
43
47
463
12
91
40
406
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
—
—
—
—
—
—
9.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.02%
—
—
—
—
—
—
5
20
47
477
Other specified pulpit
K04.08 [2000502703]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.81%
cases:0.00%
controls:1.58%
—
—
—
—
—
—
cases:0.00%
controls:2.37%
cases:0.00%
controls:4.02%
0
14
51
484
0
8
52
498
—
—
—
0
12
52
494
0
20
52
477
Extraction of tooth
EBA00 [2001301923]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
0
6
52
500
—
—
—
—
—
doxepin; oral, parenteral
N06AA12 [21604699]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
Pediatric Endocrinology
OMOP4822030 [45756809]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.62%
—
—
—
—
—
—
0
13
52
484
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
—
—
—
—
—
1.8e+00
6.8e-03
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:1.78%
cases:11.54%
controls:11.47%
—
—
—
—
—
5
9
47
497
6
57
46
440
empagliflozin; oral
A10BK03 [1123740]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.81%
cases:0.00%
controls:1.19%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
0
9
51
489
0
6
52
500
—
—
—
0
7
52
499
—
Pain in limb
M79.6 [45587063]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
0
11
52
495
—
Anxiety disorder, unspecified
F41.9 [45542849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
enalapril and diuretics
C09BA02 [21601804]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
7
52
490
Diabetes mellitus arising in pregnancy
O24.4 [45543922]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
490
—
—
—
—
—
—
Adhesive capsulitis of shoulder
M75.0 [45533931]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
cases:11.54%
controls:4.23%
—
—
—
—
—
0
7
52
499
6
21
46
476
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.43%
—
—
—
—
—
—
5
22
47
475
esomeprazole; oral, parenteral
A02BC05 [21600100]
8.5e-01
1.3e+00
—
—
—
—
—
cases:9.80%
controls:4.42%
cases:9.62%
controls:2.77%
—
—
—
—
—
—
—
—
—
—
5
22
46
476
5
14
47
492
—
—
—
—
—
Intraoral radiographic dental examination
EB1AA [2001301903]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
—
0
11
52
495
—
—
—
—
—
Chronic tonsillitis
J35.0 [45548113]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
propranolol; oral, parenteral
C07AA05 [21601670]
—
-1.0e+50
—
—
—
—
9.3e-01
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.02%
—
0
5
52
501
—
—
—
—
5
20
47
477
Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
52
501
—
ethylmorphine; oral
R05DA01 [21603397]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
choriogonadotropin alfa; parenteral
G03GA08 [21602606]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Teeth/gum symptom/complaint
D19 [2002000318]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
—
—
—
—
—
0
10
52
496
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
487
—
—
—
—
—
—
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
prednisolone
S01BA04 [21603621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Blasts/Leukocytes in Blood
26446-5 [3025159]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
—
—
—
—
—
0
10
52
487
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
combinations of corticosteroids
D07XB30 [21602188]
2.7e-01
—
—
—
—
—
1.3e-01
cases:9.80%
controls:7.63%
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:10.26%
5
38
46
460
—
—
—
—
—
6
51
46
446
Diabetic background retinopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.00*E10.3 [2000503930]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Cephalometry with X-ray
EB1MA [2001301916]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
51
488
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
—
—
—
—
—
—
6.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:17.31%
controls:9.66%
—
—
—
—
—
—
9
48
43
449
Fissure sealant
SCE00 [2001310316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Supplier / Service Provider
OMOP5117446 [33004]
-1.2e+00
—
-1.0e+50
—
—
—
—
cases:9.80%
controls:25.90%
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
5
129
46
369
—
0
5
52
501
—
—
—
—
formoterol and budesonide
R03AK07 [21603281]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Supine thorax X-ray examination
GD1QA [2001303648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Low back symptom/complaint
L03 [2002000628]
-1.0e+50
—
—
—
—
—
1.3e+00
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:2.82%
0
7
51
491
—
—
—
—
—
5
14
47
483
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.3e-01
—
—
—
—
—
-1.9e-02
cases:11.76%
controls:10.44%
—
—
—
—
—
—
—
—
—
—
cases:13.46%
controls:13.68%
6
52
45
446
—
—
—
—
—
7
68
45
429
clindamycin; oral, parenteral
J01FF01 [21602985]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:2.82%
—
—
—
—
—
0
5
52
501
0
14
52
483
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
—
—
—
—
—
—
2.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:8.85%
—
—
—
—
—
—
6
44
46
453
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
7
52
490
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.82%
0
9
51
489
—
—
—
—
—
0
14
52
483
alendronic acid; oral
M05BA04 [21604152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
X-ray examination of the lungs in one projection
GD1PA [2001303645]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Subjective visual disturbances
H53.1 [45557467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Appendectomy
JEA00 [2001304802]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
hydrocortisone butyrate
D07AB02 [21602106]
4.5e-01
—
—
—
—
—
5.7e-01
cases:11.76%
controls:7.83%
—
—
—
—
—
—
—
—
—
—
cases:13.46%
controls:8.05%
6
39
45
459
—
—
—
—
—
7
40
45
457
temazepam; oral
N05CD07 [21604642]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.01%
cases:0.00%
controls:1.19%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
cases:0.00%
controls:1.61%
0
10
51
488
0
6
52
500
—
—
—
0
8
52
498
0
8
52
489
Periodontal treatment by dental hygienist
SDE02 [2001310350]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
tamsulosin; oral
G04CA02 [21602669]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
489
—
—
—
—
—
—
terbutaline; inhalant
R03AC03 [21603257]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
cases:0.00%
controls:1.19%
cases:0.00%
controls:1.19%
—
—
—
0
6
52
500
—
—
0
6
52
500
0
6
52
500
—
Otolaryngology
4 [38004449]
5.1e-02
—
—
—
—
7.1e-01
—
cases:11.76%
controls:11.24%
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.94%
—
—
6
56
45
442
—
—
—
—
5
25
47
481
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
—
0
9
52
497
—
frovatriptan; oral
N02CC07 [21604382]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Fracture of lower end of radius
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Teeth/gum disease
D82 [2002000380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:5.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
28
51
470
—
—
—
—
—
—
nitrofurantoin; oral
J01XE01 [21603058]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:2.21%
—
—
—
—
—
—
5
11
47
486
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
490
—
—
—
—
—
—
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Gonarthrosis [arthrosis of knee]
M17 [45601350]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
5
51
493
—
—
—
—
—
0
6
52
491
Acute lymphoblastic leukaemia [ALL]
C91.0 [45537873]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.01%
cases:0.00%
controls:1.98%
—
—
—
—
cases:0.00%
controls:1.19%
cases:0.00%
controls:1.78%
cases:0.00%
controls:2.01%
0
10
51
488
0
10
52
496
—
—
0
6
52
500
0
9
52
497
0
10
52
487
budesonide; inhalant
R03BA02 [21603285]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
0
6
52
500
—
—
—
—
cromoglicic acid; nasal
R01AC01 [21605033]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
0
6
51
492
—
—
—
—
—
0
8
52
489
Outlet vacuum delivery
MAE00 [2001306882]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
3.1e-01
—
—
—
—
8.0e-01
1.4e-02
cases:15.69%
controls:12.05%
—
—
—
—
—
—
—
—
cases:15.38%
controls:7.51%
cases:21.15%
controls:20.93%
8
60
43
438
—
—
—
—
8
38
44
468
11
104
41
393
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
4.7e-01
1.3e+00
—
1.0e+50
—
5.9e-01
2.9e-01
cases:25.49%
controls:17.67%
cases:21.15%
controls:6.72%
—
—
cases:11.54%
controls:0.00%
—
—
cases:11.54%
controls:6.72%
cases:21.15%
controls:16.70%
13
88
38
410
11
34
41
472
—
6
0
46
506
—
6
34
46
472
11
83
41
414
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
0
9
52
497
—
—
—
0
8
52
498
—
Pneumonia, unspecified
J18.9 [45601123]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.22%
0
14
51
484
—
—
—
—
—
0
16
52
481
Nonorganic insomnia
F51.0 [45552492]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Foreign body in skin
S15 [2002000980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Pregnancy confirmed
Z32.1 [45566418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
489
—
—
—
—
—
—
Body mass index
60621009 [4245997]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:0.00%
—
—
—
—
—
—
6
0
46
497
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
6
51
492
—
—
—
—
0
6
52
500
—
hydrocortisone
D07XA01 [21602180]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
52
500
—
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
51
485
—
—
—
—
—
—
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Acute cystitis
N30.0 [45601724]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:3.42%
—
—
—
—
—
—
5
17
47
480
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
0
8
52
498
—
—
—
—
—
Laboratory Visit
OMOP4822461 [32036]
-3.0e-01
3.0e-02
1.1e+00
—
1.1e+00
1.1e-01
-1.4e-02
cases:17.65%
controls:22.49%
cases:19.23%
controls:18.77%
cases:17.31%
controls:6.32%
—
—
cases:13.46%
controls:5.14%
cases:23.08%
controls:21.15%
cases:32.69%
controls:33.00%
9
112
42
386
10
95
42
411
9
32
43
474
—
7
26
45
480
12
107
40
399
17
164
35
333
Adaptation disorder with mixed anxiety and depression
F43.22 [2000502003]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Cardiology
6 [38004451]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
0
11
52
495
—
—
—
0
7
52
499
—
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
—
—
—
—
—
—
8.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:7.04%
—
—
—
—
—
—
8
35
44
462
No disease
A97 [2002000230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
490
—
—
—
—
—
—
tranexamic acid; oral, parenteral
B02AA02 [21601036]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
51
486
—
—
—
—
—
—
Epistaxis
R04.0 [45606791]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
sitagliptin; oral
A10BH01 [21600784]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
0
5
51
493
0
6
52
500
—
—
—
—
0
5
52
492
Essential (primary) hypertension
I10 [45591453]
—
—
—
—
—
—
3.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.46%
controls:9.66%
—
—
—
—
—
—
7
48
45
449
Extensive health check-up of children and adolescents
SPAT1316 [2001700417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
490
—
—
—
—
—
—
Hematology
82 [38004501]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
lisinopril; oral
C09AA03 [21601787]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
Mixed specific developmental disorders
F83 [45595922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
492
—
—
—
—
—
—
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
—
—
9.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:3.82%
—
—
—
—
—
—
5
19
47
478
Stomatognathic treatment, simple
SHA01 [2001310405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
fluticasone, combinations
R01AD58 [43534837]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:2.62%
—
—
—
—
—
—
5
13
47
484
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
-1.0e+50
—
—
—
—
—
4.7e-01
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:6.24%
0
6
51
492
—
—
—
—
—
5
31
47
466
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Preventive oral health care
SCA02 [2001310303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
490
—
—
—
—
—
—
allopurinol; oral, parenteral
M04AA01 [21604131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Acute appendicitis, unspecified
K35.9 [45557651]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
7
52
490
tizanidine; oral
M03BX02 [21604116]
2.5e-01
—
—
—
—
-1.0e+50
4.2e-01
cases:9.80%
controls:7.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.16%
cases:13.46%
controls:9.26%
5
39
46
459
—
—
—
—
0
16
52
490
7
46
45
451
Pharmacy visit
OMOP4822462 [581458]
5.3e-01
7.0e-01
6.3e-02
—
6.0e-01
2.6e-02
2.2e-02
cases:94.12%
controls:90.36%
cases:82.69%
controls:70.36%
cases:34.62%
controls:33.20%
—
—
cases:48.08%
controls:33.60%
cases:75.00%
controls:74.51%
cases:92.31%
controls:92.15%
48
450
3
48
43
356
9
150
18
168
34
338
—
25
170
27
336
39
377
13
129
48
458
4
39
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
—
—
—
—
—
—
9.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:17.31%
controls:7.44%
—
—
—
—
—
—
9
37
43
460
Tension-type headache
G44.2 [45581495]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Physical Medicine And Rehabilitation
25 [38004468]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:6.04%
—
—
—
—
—
—
5
30
47
467
cefuroxime; oral, parenteral
J01DC02 [21602884]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
0
5
52
501
—
—
—
—
0
5
52
492
dexamethasone
S01CB01 [21603664]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Urinary frequency/urgency
U02 [2002001138]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
ECG with 12 standard connections
XF400 [2001303368]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
487
—
—
—
—
—
—
orphenadrine, combinations
M03BC51 [21604113]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:2.01%
—
—
—
—
—
—
6
10
46
487
calcium (different salts in combination); oral
A12AA20 [21600872]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
0
7
52
499
—
0
8
52
498
—
—
Periodontal treatment
SDA03 [2001310328]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:4.42%
cases:0.00%
controls:2.77%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
0
22
51
476
0
14
52
492
—
—
—
0
9
52
497
—
Cough
R05 [45606792]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.81%
0
8
51
490
—
—
—
—
—
0
9
52
488
Audiology
64 [38004489]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
52
500
—
Snapping jaw
K07.60 [2000502791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-2.4e-01
2.0e-01
—
—
—
3.9e-01
1.0e-01
cases:11.76%
controls:14.46%
cases:11.54%
controls:9.68%
—
—
—
—
—
—
cases:17.31%
controls:12.45%
cases:25.00%
controls:23.14%
6
72
45
426
6
49
46
457
—
—
—
9
63
43
443
13
115
39
382
insulin (human); parenteral
A10AB01 [21600715]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:9.84%
cases:0.00%
controls:8.50%
cases:0.00%
controls:3.36%
—
—
cases:0.00%
controls:2.96%
—
—
—
—
0
49
51
449
0
43
52
463
0
17
52
489
—
0
15
52
491
—
—
diclofenac
D11AX18 [21602355]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Chronic maxillary sinusitis
J32.0 [45586667]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Phase of life problem adult
P25 [2002000820]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
combinations of corticosteroids
D07AB30 [21602118]
2.7e-01
—
—
—
—
—
1.3e-01
cases:9.80%
controls:7.63%
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:10.26%
5
38
46
460
—
—
—
—
—
6
51
46
446
Examination for driving licence
Z02.4 [45552056]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
—
—
—
—
—
0
10
52
487
Placement of modified orthodontic arch wire
SJD20 [2001310439]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
desogestrel
G03AC09 [21602505]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
0
5
52
501
—
—
—
0
5
52
501
—
isosorbide mononitrate; oral
C01DA14 [21600324]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.81%
cases:0.00%
controls:1.19%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
9
51
489
0
6
52
500
—
—
—
0
6
52
500
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:5.03%
—
—
—
—
—
—
5
25
47
472
Atrial fibrillation and flutter
I48 [45596206]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.81%
0
11
51
487
—
—
—
—
0
5
52
501
0
9
52
488
Laceration/cut
S18 [2002000983]
—
-1.0e+50
—
—
—
—
7.8e-01
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
cases:9.62%
controls:4.63%
—
0
8
52
498
—
—
—
—
5
23
47
474
mercaptopurine
L01BB02 [21601428]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
Seborrhoeic keratosis
L82 [45548208]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
0
8
52
498
—
—
—
—
—
Localized oedema
R60.0 [45597193]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
cromoglicic acid
S01GX01 [21605085]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
0
6
52
500
—
—
—
0
5
52
501
—
Functional capacity evaluation
443351003 [40481051]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
5
52
501
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
3.5e-01
-1.0e+50
—
—
—
7.6e-01
4.7e-01
cases:13.73%
controls:10.04%
cases:0.00%
controls:5.93%
—
—
—
—
—
—
cases:9.62%
controls:4.74%
cases:25.00%
controls:17.30%
7
50
44
448
0
30
52
476
—
—
—
5
24
47
482
13
86
39
411
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
—
—
—
—
—
9.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:4.63%
—
—
—
—
—
—
6
23
46
474
Dental caries
K02 [45552906]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
latanoprost
S01EE01 [21603710]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Examination of eyes and vision
Z01.0 [45566391]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:3.01%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
0
15
51
483
—
—
—
—
0
7
52
499
—
Orthodontic treatment/control appointment
SJX20 [2001310454]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
phenylephrine, combinations
S01GA55 [21605082]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-1.1e-01
2.3e-01
1.7e+00
—
—
3.6e-01
1.3e-01
cases:17.65%
controls:19.28%
cases:17.31%
controls:14.23%
cases:11.54%
controls:2.37%
—
—
—
—
cases:21.15%
controls:15.81%
cases:32.69%
controls:29.98%
9
96
42
402
9
72
43
434
6
12
46
494
—
—
11
80
41
426
17
149
35
348
spironolactone; oral
C03DA01 [21601534]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
5
52
501
—
—
—
—
—
Presence of intraocular lens
Z96.1 [45585885]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
491
—
—
—
—
—
—
bisoprolol; oral
C07AB07 [21601689]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:6.13%
cases:0.00%
controls:1.98%
—
—
cases:0.00%
controls:2.17%
cases:0.00%
controls:6.92%
—
—
—
0
31
52
475
0
10
52
496
—
0
11
52
495
0
35
52
471
—
Extensive health check-up of expecting family
SPAT1197 [2001700298]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
10
51
488
—
—
—
—
—
0
6
52
491
12 lead EKG panel
34534-8 [3044889]
—
—
—
—
—
—
4.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.38%
controls:10.87%
—
—
—
—
—
—
8
54
44
443
sertraline; oral
N06AB06 [21604714]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.41%
cases:0.00%
controls:1.38%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
0
7
51
491
0
7
52
499
—
—
—
0
8
52
498
—
Fear sexually transm dis female
X23 [2002001308]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Type 1 diabetes mellitus
E10 [45576436]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
489
—
—
—
—
—
—
insulin lispro; parenteral
A10AB04 [21600718]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
0
6
52
500
—
0
9
52
497
—
—
sildenafil; oral
G04BE03 [21602648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
51
488
—
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
489
—
—
—
—
—
—
Benign paroxysmal vertigo
H81.1 [45572061]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
erdosteine; oral
R05CB15 [21603394]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.02%
0
5
51
493
—
—
—
—
—
0
15
52
482
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
5
52
501
—
—
—
—
—
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
7
52
490
pH of Serum or Plasma
2753-2 [3018418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
51
486
—
—
—
—
—
—
Disease/condition unspecnature/site
A99 [2002000232]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
6
52
491
Menopausal and female climacteric states
N95.1 [45548683]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.02%
0
5
51
493
—
—
—
—
—
0
15
52
482
Other fall from one level to another
W17 [45756255]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Respiratory infection other
R83 [2002000951]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
0
5
52
501
—
—
—
—
—
beclometasone; inhalant
R03BA01 [21603284]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
0
5
52
501
—
—
—
—
0
5
52
492
One-surface restoration
SFA10 [2001310358]
—
-1.0e+50
—
—
—
—
-2.0e-01
—
—
cases:0.00%
controls:2.77%
—
—
—
—
—
—
—
—
cases:9.62%
controls:11.47%
—
0
14
52
492
—
—
—
—
5
57
47
440
terbinafine; oral
D01BA02 [21601967]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.41%
—
—
—
—
—
—
0
12
52
485
Dentistry
C5 [903277]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
cases:0.00%
controls:4.43%
—
0
11
52
495
—
—
—
0
9
52
497
0
22
52
475
Routine postpartum follow-up
Z39.2 [45547306]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
487
—
—
—
—
—
—
roxithromycin; oral
J01FA06 [21602974]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:5.22%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
cases:0.00%
controls:3.82%
0
26
51
472
—
—
—
—
0
10
52
496
0
19
52
478
Coloscopy
UJF32 [2001305029]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
1.8e+00
—
—
—
—
—
—
cases:9.80%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
5
9
46
489
—
—
—
—
—
—
papillomavirus (human types 16, 18)
J07BM02 [21601368]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Pregnancy
W78 [2002001269]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
51
488
—
—
—
—
—
—
metformin; oral
A10BA02 [21600747]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
51
485
—
—
—
—
—
—
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
52
492
Neck symptom/complaint
L01 [2002000626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
diclofenac; ointment
M02AA15 [21604051]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
8
52
489
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
493
—
—
—
—
—
—
timolol, combinations
S01ED51 [21603705]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.00%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.21%
0
5
51
493
0
5
52
501
—
—
—
0
5
52
501
0
6
52
491
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.54%
controls:3.62%
—
—
—
—
—
—
6
18
46
479
fusidic acid
D09AA02 [21602265]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
52
501
—
Acute upper respiratory infection, unspecified
J06.9 [45562437]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
—
0
8
52
498
—
—
—
—
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.20%
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
0
6
51
492
0
5
52
501
—
—
—
—
—
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.77%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
0
14
52
492
—
—
—
0
7
52
499
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
148
2.37
2.83
4.7
3.1
—
—
estimate
—
0
0
14
58
2.78
2.57
1.5
1.5
—
—
—
0
0
34
214
2.18
2.51
7.6
4.4
83.86
35.14
e6/l
0.37
29
145
9
27
3.68
2.50
2.0
20.1
1.29
1.15
mg/l
—
9
27
31
192
2.13
2.35
4.6
2.5
—
—
—
0
0
13
60
2.44
1.92
6.2
3.5
1.75
1.78
%
0.04
13
53
18
97
2.16
1.89
4.6
4.1
—
—
—
0
0
22
131
2.00
1.78
8.8
3.7
7.37
7.39
ph
2.29
17
91
32
217
1.90
1.78
12.5
8.7
1.23
1.22
mmol/l
0.18
32
202
21
125
1.98
1.69
4.0
2.7
—
—
—
0
0
50
403
1.91
1.52
8.7
4.7
—
—
—
0
0
10
46
2.38
1.48
2.2
2.0
6.60
6.29
ph
—
5
34
6
23
2.76
1.40
3.3
1.7
1.02
1.02
ratio
—
6
23
6
25
2.53
1.27
2.3
2.0
10.73
7.14
nmol/l
—
6
25
28
200
1.68
1.21
2.2
1.9
93.46
97.60
pmol/l
0.20
15
97
40
314
1.67
1.21
5.7
3.9
0.00
0.00
estimate
—
10
67
0
34
0.00
1.19
0.0
1.1
—
3.92
—
0
20
10
51
2.13
1.18
7.6
14.7
24.63
25.06
mmol/l
—
10
51
0
36
0.00
1.18
0.0
1.1
—
0.43
—
0
24
5
21
2.49
1.11
11.0
4.4
—
—
—
0
0
9
47
2.05
1.07
6.1
1.9
—
0.00
estimate
—
0
15
5
22
2.37
1.05
12.4
8.0
24.10
24.38
mmol/l
—
5
22
9
50
1.92
1.01
2.3
5.6
77.89
51.99
ng/l
—
9
44
9
50
1.92
1.01
1.2
1.5
—
—
—
0
0
9
52
1.84
0.97
1.2
1.6
—
—
—
0
0
39
316
1.55
0.95
5.9
3.8
0.00
0.00
estimate
—
10
68
8
46
1.84
0.86
9.1
10.5
102.50
104.93
mmol/l
—
8
46
8
47
1.79
0.84
15.0
6.7
0.85
1.39
mmol/l
—
8
41
38
312
1.49
0.83
6.1
3.8
0.00
0.00
estimate
—
10
67
25
188
1.52
0.83
2.1
2.3
—
—
—
0
0
9
53
1.80
0.79
11.1
11.9
—
—
—
0
0
0
27
0.00
0.79
0.0
1.1
—
9.98
—
0
15
0
27
0.00
0.79
0.0
1.1
—
2.27
—
0
15
36
297
1.45
0.74
2.5
2.7
—
—
estimate
—
0
0
7
42
1.74
0.71
5.0
6.4
7.41
7.42
ph
—
7
37
19
139
1.51
0.70
3.1
3.2
23.00
20.10
ng/l
0.13
11
77
23
179
1.43
0.63
5.3
2.8
0.00
0.00
estimate
—
7
54
6
39
1.59
0.54
7.0
4.9
3.03
9.11
ug/l
—
6
30
7
49
1.48
0.47
3.9
3.3
—
—
—
0
0
8
56
1.48
0.44
1.1
1.5
—
—
—
0
0
5
31
1.66
0.44
1.4
1.9
18.00
28.17
u/ml
—
5
31
0
15
0.00
0.42
0.0
1.3
—
—
—
0
0
5
34
1.51
0.41
2.0
3.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
4.3
—
285.76
—
0
17
5
35
1.46
0.40
1.4
1.8
—
—
—
0
0
5
36
1.42
0.39
1.2
1.5
—
—
—
0
0
5
36
1.42
0.39
1.4
1.2
—
—
—
0
0
26
222
1.28
0.37
1.8
2.0
—
—
—
0
0
12
91
1.39
0.37
9.6
3.0
11.80
29.50
ng/l
—
5
48
6
42
1.47
0.37
1.3
1.4
—
—
—
0
0
23
194
1.28
0.36
2.4
1.9
—
—
—
0
0
27
233
1.26
0.35
1.5
1.8
—
—
—
0
0
14
111
1.33
0.33
2.4
1.6
—
—
—
0
0
25
216
1.25
0.32
1.6
1.6
3.28
1.23
u/ml
—
6
46
43
395
1.24
0.31
10.4
6.6
91.70
81.27
u/l
0.26
43
371
8
65
1.26
0.28
1.3
1.8
—
—
—
0
0
23
200
1.23
0.27
6.1
7.1
—
—
—
0
0
5
37
1.38
0.24
3.4
6.6
—
—
—
0
0
17
197
0.82
0.23
1.9
1.9
—
—
—
0
0
17
145
1.23
0.23
6.5
4.6
—
—
—
0
0
5
39
1.30
0.23
3.0
6.8
—
0.42
—
0
12
5
41
1.24
0.22
3.0
7.2
—
0.46
—
0
13
5
42
1.21
0.22
13.6
10.1
1.36
1.21
mmol/l
—
5
42
0
10
0.00
0.21
0.0
2.6
—
28.20
—
0
10
0
10
0.00
0.21
0.0
6.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.4
—
686.00
—
0
5
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
7.5
—
—
—
0
0
0
13
0.00
0.21
0.0
5.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.9
—
55.49
—
0
14
7
60
1.19
0.18
1.7
1.7
829.41
1097.34
nmol/l
—
7
46
28
256
1.16
0.18
5.2
3.4
6.29
6.29
ph
0.00
14
140
5
67
0.73
0.18
5.4
1.5
—
—
—
0
0
5
67
0.73
0.18
5.4
1.5
—
—
—
0
0
5
68
0.71
0.18
5.4
1.5
—
—
—
0
0
5
68
0.71
0.18
6.0
1.5
—
—
—
0
0
8
69
1.18
0.17
1.3
1.2
—
—
—
0
0
22
198
1.16
0.17
4.3
2.3
—
—
—
0
0
8
72
1.13
0.16
2.9
6.4
29.75
29.14
s
—
8
72
60
584
1.23
0.15
18.2
12.2
19.78
18.32
mg/l
0.16
50
449
13
113
1.19
0.14
1.2
1.6
1376.96
996.27
mu/l
0.48
13
98
35
330
1.12
0.13
7.4
7.9
0.20
0.19
e9/l
0.15
30
295
16
143
1.16
0.13
1.3
1.9
—
—
—
0
0
33
313
1.11
0.10
7.8
7.8
0.56
0.52
e9/l
0.28
28
274
13
116
1.15
0.10
4.4
3.7
299.92
297.17
umol/l
0.04
13
109
33
314
1.10
0.09
7.8
7.8
0.03
0.04
e9/l
0.20
28
274
6
55
1.10
0.09
1.5
1.5
—
—
—
0
0
6
56
1.08
0.09
1.7
1.1
—
—
—
0
0
23
245
0.91
0.09
2.7
2.3
—
—
—
0
0
18
190
0.93
0.04
1.8
1.7
1.81
2.18
g/l
0.35
13
105
25
241
1.06
0.03
5.5
3.4
0.00
0.02
estimate
—
8
56
30
301
0.99
0.00
8.5
7.4
55.96
55.48
%
0.07
30
292
17
175
0.96
0.00
8.7
4.0
0.00
0.00
estimate
—
9
63
36
355
1.03
0.00
8.7
10.1
3.81
3.98
e9/l
0.24
31
309
20
198
1.01
0.00
6.1
9.2
—
—
—
0
0
33
326
1.02
0.00
7.9
7.6
2.34
2.17
e9/l
0.20
28
300
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
6
60
1.00
-0.00
2.3
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
1.47
—
0
7
0
6
0.00
-0.00
0.0
12.2
—
0.57
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.3
—
3.15
—
0
8
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
2.96
—
0
6
6
61
0.98
-0.00
2.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
8.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
5
58
0.85
-0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.7
—
10.33
—
0
9
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
7.80
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
0.58
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_SUPERNUMERARY_URETER – Supernumerary ureter

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).